Terminal modifications independent cell-free RNA sequencing enables sensitive early cancer detection and classification

Nat Commun. 2024 Jan 2;15(1):156. doi: 10.1038/s41467-023-44461-y.

Abstract

Cell-free RNAs (cfRNAs) offer an opportunity to detect diseases from a transcriptomic perspective, however, existing techniques have fallen short in generating a comprehensive cell-free transcriptome profile. We develop a sensitive library preparation method that is robust down to 100 µl input plasma to analyze cfRNAs independent of their 5'-end modifications. We show that it outperforms adapter ligation-based method in detecting a greater number of cfRNA species. We perform transcriptome-wide characterizations in 165 lung cancer, 30 breast cancer, 37 colorectal cancer, 55 gastric cancer, 15 liver cancer, and 133 cancer-free participants and demonstrate its ability to identify transcriptomic changes occurring in early-stage tumors. We also leverage machine learning analyses on the differentially expressed cfRNA signatures and reveal their robust performance in cancer detection and classification. Our work sets the stage for in-depth study of the cfRNA repertoire and highlights the value of cfRNAs as cancer biomarkers in clinical applications.

MeSH terms

  • Biomarkers, Tumor / genetics
  • Cell-Free Nucleic Acids* / genetics
  • Gene Expression Profiling / methods
  • Humans
  • Lung Neoplasms* / diagnosis
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / pathology
  • RNA
  • Sequence Analysis, RNA / methods
  • Transcriptome / genetics

Substances

  • Cell-Free Nucleic Acids
  • RNA
  • Biomarkers, Tumor